Clinical trials
Breast Cancer Risk clinical trials
Below are recruiting breast cancer risk clinical trials, each written for real people, not researchers. We’re tracking 743 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06081244RecruitingPhase 3
Testing sacituzumab govitecan with or without pembrolizumab for early triple-negative breast cancer
This trial tests a two-drug combination (sacituzumab govitecan and pembrolizumab) versus sacituzumab govitecan alone before surgery for low-risk, triple-negative breast cancer that hasn't spread. The goal is to see which approach works better at shrinking tumors.
Baden-Baden, Baden-WurttembergAges 18 years+ - NCT07047495Recruiting
Personalized radiation therapy for early breast cancer
This trial is testing a way to personalize radiation therapy for people with early-stage breast cancer. It may help make treatment more precise and reduce side effects.
Milan, ItalyAges 18 years+ - NCT05852223RecruitingPhase 2
Pembrolizumab for high-risk thyroid cancer that cannot be fully removed
This study tests pembrolizumab (an immune therapy) in people with high-risk thyroid cancer that is hard to treat with surgery alone. It looks at whether this drug can reduce persistent or recurrent cancer after your planned treatment.
Pavia, LombardyAges 18 years+ - NCT04525989Recruiting
Short-course proton vs photon radiation before rectal surgery
This study compares two types of pre-surgery radiation—protons versus standard photons—in people with high-risk rectal cancer. The goal is to shrink and control the tumor while safely getting you ready for surgery, and to see which approach works better.
Stockholm, SolnaAges 18 years+ - NCT05216900Recruiting
Breast reconstruction with radiation given before surgery
This study looks at how breast reconstruction works when radiation is planned around the time of surgery, including in some people before surgery depending on lymph node results. It may help improve safety and outcomes for people needing mastectomy and chest/radiation therapy.
Bilthoven, UtrechtAges 18–75 - NCT06146231Recruiting
Breast reconstruction with Motiva implants and fat grafting
This study tests a new breast reconstruction method using Motiva Flora implants and your own fat to rebuild the breast after a mastectomy. It is for women who need tissue expansion as part of their reconstruction and have completed cancer treatments at least one year earlier.
GhentAges 18 years+ - NCT06702800Recruiting
Using tumor models to predict breast cancer drug response
This study uses a personal lab-grown model of your tumor (called an organoid) to help predict which drugs are most likely to work for your specific breast cancer. It is open to both early-stage and advanced breast cancer patients who are about to start or are already receiving treatment.
Changsha, HunanAges 18–70 - NCT07660055RecruitingPhase 1
Radioactive drug for advanced solid tumors
This trial tests a new radioactive drug (called 177Lu-DWJ155) that targets and kills cancer cells, along with a similar imaging agent (68Ga-DWJ155) used to see where the drug goes in the body. It is for people with certain advanced solid tumors that have not responded to standard therapies.
Omaha, NebraskaAges 18 years+ - NCT06082180RecruitingPhase 3
Preventive neck lymph node removal in low-risk thyroid cancer
This trial is for people with low-risk papillary thyroid cancer. It compares two surgical approaches: one that removes just the thyroid gland, and another that also removes some lymph nodes in the center of the neck as a preventive measure. The goal is to see if removing these lymph nodes helps prevent the cancer from coming back.
Beijing, Beijing MunicipalityAges 18–70 - NCT06817226Recruiting
Breast cancer decision tool study for Latinas
This study tests a decision-making tool for Latina breast cancer survivors or those at high risk. It aims to help you make informed choices about breast surgery and reconstruction options.
Chapel Hill, North CarolinaAges 18 years+ - NCT07321015RecruitingPhase 2
Fluzoparib after platinum for advanced triple-negative breast cancer
This trial tests the PARP inhibitor fluzoparib as a maintenance treatment for women with advanced triple-negative breast cancer whose disease responded or stabilized after platinum-based chemotherapy. The goal is to see if taking fluzoparib daily can delay cancer growth.
TianjinAges 18–75 - NCT06841354RecruitingPhase 3
Sac-TMT alone or with pembrolizumab for advanced triple-negative breast cancer
This trial tests a new drug, Sac-TMT, given alone or with an immunotherapy drug (pembrolizumab) for people with advanced triple-negative breast cancer who have not yet received any treatment for advanced disease. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
Mobile, AlabamaAges 18 years+ - NCT06188520RecruitingPhase 1/Phase 2
Study of a new drug for advanced solid tumors in women
This trial tests a new drug, AZD8421, alone or with other treatments, for women with advanced solid tumors that have not responded to prior therapies. It aims to find a safe dose and see if it can help shrink or control the cancer.
St Louis, MissouriAges 18 years+ - NCT06291896Recruiting
Testing microwave imaging for breast cancer screening
This study tests a new, safe microwave-based device (MammoWave) to screen for breast cancer. It compares the device's results with standard mammograms to see if it can find cancer early in women at average risk.
Genova, GenovaAges 45–74 - NCT07287917RecruitingPhase 1/Phase 2
Testing a new drug combo for advanced breast cancer or melanoma
This trial tests a new combination of drugs (AMXT 1501, DFMO, and standard therapies) for people with advanced solid tumors, specifically breast cancer (ER+ HER2-) or melanoma that has progressed after other treatments. The goal is to see if this combination can help shrink tumors or slow their growth.
Tucson, ArizonaAges 18 years+ - NCT05277935Recruiting
Wearable activity tracking for hormone-positive metastatic breast cancer
This study tests whether using a wearable watch and smartphone app to track activity and fitness can help monitor health in people with hormone receptor–positive, HER2-negative metastatic breast cancer while they take standard hormone therapy plus palbociclib. It mainly requires that you are already on these medicines for at least three months and can use the devices reliably.
Rio de JaneiroAges 18 years+ - NCT05416164Recruiting
Testes less radiation after a complete response to medicines
This study checks whether some people with breast cancer who have no remaining cancer after medicine (neoadjuvant systemic therapy) can safely receive less radiation. It may help reduce side effects while still keeping cancer controlled.
Amsterdam, North HollandAges 18 years+ - NCT05535413RecruitingPhase 1/Phase 2
UTD1 plus capecitabine for HER2-negative breast cancer brain mets
This trial tests whether adding a study drug called UTD1 to capecitabine can shrink or control breast cancer that has spread to the brain. It’s for people with HER2-negative metastatic breast cancer who have brain metastases and meet specific safety and lab requirements.
ChangshaAges 18–70 - NCT04743479Recruiting
AI screening for pancreatic cancer in higher-risk people
This trial uses an artificial-intelligence tool to help detect pancreatic cancer earlier and track people at higher risk. You may be asked to complete questionnaires and have imaging tests like MRI or CT to see how well the approach works.
ShanghaiAges 50–75 - NCT03396341Recruiting
Surveys after genetic risk results for certain breast cancer genes
This study asks women to complete surveys after learning their genetic risk results for certain breast cancer–related gene changes. It helps researchers understand how people respond and what they think or feel after getting these results.
Boston, MassachusettsAges 25 years+ - NCT06086132Recruiting
Preventing heart damage from cancer treatment
This trial tracks how cancer treatments affect the heart. It may help doctors find ways to prevent heart problems during your treatment.
BolognaAges 18 years+ - NCT05774678RecruitingPhase 3
Pre-surgery radiation options for invasive breast cancer
This trial compares two schedules of radiation given before mastectomy to see which works better for invasive breast cancer, followed by immediate breast reconstruction. It also studies tiny “biomarker” signals in tissue to learn why one radiation approach may help more.
Houston, TexasAges 18 years+ - NCT06856499RecruitingPhase 1
Cirtuvivint and Olaparib for BRCA-related ovarian cancer
This trial tests a combination of two targeted drugs, cirtuvivint and olaparib, for a specific type of ovarian cancer that no longer responds to platinum chemotherapy. It may be an option if you have a BRCA mutation or HRD-positive tumor and have already tried a PARP inhibitor.
Aurora, ColoradoAges 18 years+ - NCT06028022RecruitingPhase 2
Reishi mushroom for fatigue and joint/muscle pain in breast cancer
This trial tests whether a reishi mushroom extract can help reduce fatigue and joint or muscle pain in people with breast cancer who are taking aromatase inhibitors. If you have these symptoms, you may be able to join.
Albert Lea, MinnesotaAges 18 years+
Hear when a new Breast Cancer Risk trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for breast cancer risk?
- Yes. Clin2 currently lists 743 recruiting breast cancer risk studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a breast cancer risk trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a breast cancer risk trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.